Hypokalemia after rituximab administration in nephrotic syndrome: two case reports

Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse events with the administration of rituximab. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yiyun, Ding, Lin, An, Xin, Zhao, Yi, Li, Xianhua, Yang, Xiangdong, Xiao, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354934/
https://www.ncbi.nlm.nih.gov/pubmed/37464309
http://dx.doi.org/10.1186/s12882-023-03079-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354934/
https://www.ncbi.nlm.nih.gov/pubmed/37464309
http://dx.doi.org/10.1186/s12882-023-03079-4

Ejemplares similares